These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 31678263)

  • 21. Exploratory IND: a new regulatory strategy for early clinical drug development in the United States.
    Sarapa N
    Ernst Schering Res Found Workshop; 2007; (59):151-63. PubMed ID: 17117721
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An Analysis of Antibacterial Drug Development Trends in the United States, 1980-2019.
    Dheman N; Mahoney N; Cox EM; Farley JJ; Amini T; Lanthier ML
    Clin Infect Dis; 2021 Dec; 73(11):e4444-e4450. PubMed ID: 32584952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.
    BioDrugs; 2003; 17(1):69-72. PubMed ID: 12534322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Review on: Phase '0' Clinical Trials or Exploratory Investigational New Drug.
    Gawai AA; Shaikh F; Gadekar M; Deokar N; Kolhe S; Biyani KR
    Turk J Pharm Sci; 2017 Apr; 14(1):84-89. PubMed ID: 32454598
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The HIV/AIDS vaccine researchers' orientation to the process of preparing a US FDA application for an investigational new drug (IND): what it is all about and how you start by preparing for your pre-IND meeting.
    Shapiro SZ
    Vaccine; 2002 Jan; 20(9-10):1261-80. PubMed ID: 11818145
    [No Abstract]   [Full Text] [Related]  

  • 27. Regulatory issues of importance to developing anti-HIV therapeutics.
    Hastings KL
    Toxicol Pathol; 1996; 24(3):278-80. PubMed ID: 8736383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of secondary pharmacology assays received by the US Food and Drug Administration.
    Scott C; Dodson A; Saulnier M; Snyder K; Racz R
    J Pharmacol Toxicol Methods; 2022; 117():107205. PubMed ID: 35926773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The "treatment IND (investigational new drugs)": public policy considerations.
    Roberts C; Palumbo FB
    J Pharm Mark Manage; 1988; 3(1):41-59. PubMed ID: 10290888
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulation of research: is it a drug trial or a supplement trial?
    Chen ST
    Fitoterapia; 2011 Jan; 82(1):14-6. PubMed ID: 21073930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
    Harapanhalli RS
    Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FDA drug classification system.
    Sanborn MD; Godwin HN; Pessetto JD
    Am J Hosp Pharm; 1991 Dec; 48(12):2659-62. PubMed ID: 1814217
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Jul; 73(136):40453-63. PubMed ID: 18850678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.
    Sacks LV; Shamsuddin HH; Yasinskaya YI; Bouri K; Lanthier ML; Sherman RE
    JAMA; 2014 Jan 22-29; 311(4):378-84. PubMed ID: 24449316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigational new drug safety reporting requirements for human drug and biological products and safety reporting requirements for bioavailability and bioequivalence studies in humans. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2010 Sep; 75(188):59935-63. PubMed ID: 20879180
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigational new drug, antibiotic, and biological product applications; clinical hold and termination--FDA. Final rule.
    Fed Regist; 1992 Apr; 57(73):13244-9. PubMed ID: 10118458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The IND application.
    Ferkany JW; Williams M
    Curr Protoc Pharmacol; 2008 Sep; Chapter 9():Unit 9.10. PubMed ID: 22294234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006.
    Wang Y; Bhattaram AV; Jadhav PR; Lesko LJ; Madabushi R; Powell JR; Qiu W; Sun H; Yim DS; Zheng JJ; Gobburu JV
    J Clin Pharmacol; 2008 Feb; 48(2):146-56. PubMed ID: 18199891
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessing Animal Models of Bacterial Pneumonia Used in Investigational New Drug Applications for the Treatment of Bacterial Pneumonia.
    Waack U; Weinstein EA; Farley JJ
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32122895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Investigational new drug applications; clinical holds--FDA. Direct final rule.
    Fed Regist; 1998 Dec; 63(239):68676-8. PubMed ID: 10187558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.